Phenoxodiol—A Chemosensitizer in the Midst of Cancer Chemoresistance

a report by
Ayesha B Alvaro, MD, PhD, Patricia Rossi, PharmD, David Brown, PhD, Aliza Leiser, MD, Michael Kelly, MD, Thomas Rutherford, MD, PhD, Alan Husband, PhD, and Gil Mor, MD, PhD

Phenoxodiol (2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl) (PXD)) is a synthetic derivative of genistein, a naturally occurring plant isoflavone. In the 1980s, genistein was discovered to have modest anticancer activity, and alterations in its structure created PXD and increased its anticancer activity without any toxicity. In vitro and in vivo studies showed PXD not only to be directly cytotoxic to a range of cancers, but also to sensitize chemoresistant ovarian cancer cells to platinums and taxanes. Recently, PXD was granted ‘fast track’ status by the US Food and Drug Administration (FDA) in its development as a chemosensitizer for platinums and taxanes for the treatment of recurrent ovarian cancer. This article summarizes what is known about PXD’s mechanism of action and the clinical studies employing this compound.

Pre-clinical Studies
Initial studies with PXD published in 2002 described its ability to inhibit the catalytic activity of DNA topoisomerase II. One year later, one of the first sets of data supporting its anticancer activity showed that it inhibits dimethylbenz(a)anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats. The molecular mapping of PXD’s mechanism of action was initially performed in ovarian cancer cells. Kamsteeg et al. showed that PXD is able to induce apoptosis in chemoresistant ovarian cancer cells both in vitro and in vivo at doses that are not toxic to normal ovarian surface epithelial cells. They showed that PXD is able to activate caspases, inhibit the FLICE-inhibitory protein (FLIP) and X-linked inhibitor of apoptosis (XIAP), which are potent apoptotic inhibitors, and, more importantly, chemosensitize ovarian cancer cells to Fas-induced apoptosis.

A more thorough characterization of the PXD-induced apoptotic pathway was later described, also using ovarian cancer cells. Alvero et al. showed that PXD induces an early activation of the apoptosis-initiating molecule caspase-2 with concomitant proteasome-dependent degradation of the apoptosis inhibitor XIAP. They also showed that in addition to previous reports showing that PXD sensitizes ovarian cancer cells to Fas-mediated apoptosis, it is able to sensitize chemoresistant cells to a wide range of chemotherapy agents, including paclitaxel, carboplatin, gemcitabine, docetaxel, and topotecan. PXD’s antiproliferative activity was studied in head and neck squamous carcinoma. Aquero et al. showed that PXD is able to induce caspase-independent clonogenic death in these cells. They further showed that PXD is able to induce the expression of cyclin-dependent kinase 2 (CDK2) and therefore induce G1-S arrest, and that this occurs as a result of pS3-independent p21 induction. In addition to its cytotoxic properties, PXD has also been shown to exhibit antiangiogenic properties. Using human umbilical vein endothelial cells, Gamble et al. showed that PXD inhibited endothelial cell proliferation, migration, and capillary tube formation. More importantly, they also showed that PXD is able to inhibit the expression of the matrix metalloproteinase (MMP)-2, which is a major matrix-degrading enzyme and is therefore important for the process of metastasis.

The sphingomyelin pathway was investigated in the search for an upstream mediator of PXD-induced toxicity in cancer cells. Sphingosine-1-phosphate (S1P), a product of sphingosine kinase (SK), has been shown to modulate a number of cell signaling processes, including the Akt pathway, resulting in the suppression of apoptosis. Conversely, ceramide, the product of sphingomyelinase, has been well characterized as an inhibitor of cell growth, a promoter of G1 cell cycle arrest, and an inducer of apoptosis. PXD inhibited the production of S1P and induced the formation of ceramide in the HeLa cells (immortalized cervical cancer cells). Furthermore, at the 2005 ASCO Annual Meeting, Cabot et al. showed that PXD promoted the formation of ceramide in head and neck (KB-3-1), ovarian (A2780), and adriamycin-resistant breast cancer (MCF-7-Adr). The demonstration that PXD is able to upregulate ceramide in the process of cell death induction correlates well with data showing that PXD activates caspase-2, since one of the upstream regulators of caspase-2 activation is ceramide.

More recent studies have identified redox molecules as potential targets for PXD action. Fine control of the intracellular redox status of cells has been shown to be critical for cell viability, growth, and function. Perturbation of key redox determinants such as the NADH/NAD+ ratio, glutathione balance, and membrane ubiquinone redox status and content can have profound effects on cells resulting in apoptosis. Scarlett et al. suggested that because of its hydrophobic character PXD may have a tendency to partition in membrane systems, and could therefore disrupt essential redox cycling at many different levels within cells and their membranes.

PXD was recently shown to bind with high affinity to a purified recombinant NADH-oxidase, compromising its ability to oxidize both NADH and ubiquinol and to catalyze protein disulfide–thiol interchange activity. This oxidase is a truncated form of a tumor-specific cell surface
respectively. The clinical outcomes of the study are summarized in
80, 200, and 400mg dose strata were 1.57, 8.14, 16.31, and 27.19µg/ml,
with no accumulation over time. The mean steady-state PXD levels in the 20,
eight-hourly dosing regimen resulted in steady-state plasma levels of drug
intolerance in any dose strata for the six months of treatment. The
eight at the 400mg dose level. There were no drug-associated toxicities or
intolerances in any dose strata with PXD. No evidence of tumor
response was observed, and the study was terminated due to the inability of
the blood to deconjugate glucuronide or sulfate moieties of PXD. Combined
with the high level of susceptibility of PXD to conjugation, this made
hematological cancers an inappropriate clinical target for PXD.

Clinical Study 3
In a phase Ila safety and efficacy study of the neoadjuvant use of oral PXD
in women with a primary diagnosis of squamous cell carcinoma or
adenocarcinoma of the cervix, vagina, or vulva, patients were treated with
PXD 50 (n=6), 100 (n=10), 400mg (n=10) eight-hourly for 28 consecutive
days on a neoadjuvant basis prior to surgical resection; 26 patients completed treatment. Tumor response was assessed over the
28-day treatment period by both a change in tumor burden using the
Response Evaluation Criteria in Solid Tumors (RECIST) and by
histochemical evidence of a biological effect (e.g. apoptosis). No
incidences of PR have been recorded (against RECIST criteria), although
many patients have shown a reduction in the sum longitudinal diameter
of between 20 and 27%. Of the six patients treated with PXD 50mg, the
incidence of stabilized disease (SD) and disease progression (DP) was two
and four, respectively. Of the eight patients treated with PXD 200mg, the
incidence of SD and DP was eight and zero, respectively. The data for the
400mg stratum have yet to be collected. This trend suggests an
antitumor effect of PXD in this setting, a fact supported by histochemical
evidence showing an increase in apoptotic index and decrease in mitotic
index in the 200mg stratum. There was one serious adverse event (SAE)
deemed definitely related to PXD: prolonged bleeding time in a patient on
the 400mg arm. The data are currently being cleaned and will be available
for analysis shortly.

Clinical Study 4
In a current phase Ib safety and efficacy study of PXD in combination
with cisplatin or carboplatin in patients with advanced or metastatic
cancer not suitable for surgery or radiotherapy, 25 patients were treated
with a oral PXD in combination with cisplatin or carboplatin. The primary
objective of this study was to determine the recommended phase II dose
of PXD in combination with cisplatin or carboplatin. Patients were given
oral PXD 50 (n=6), 100 (n=6), 400 (n=6), or 800mg (n=7) every eight
hours daily for 10 consecutive days followed by 11 days of rest. In
addition, patients received either cisplatin 50mg/m² on days two and
nine of each 21-day cycle or carboplatin area under the curve (AUC)=5
on day three every 21 days. The dose-limiting toxicity (DLT) was diarrhea
at the 800mg dose level and the maximum tolerated dose (MTD) was
determined to be 400mg orally every eight hours. In this trial there were
four serious adverse events: two cases of diarrhea, one case of
ventricular arrhythmia, and one case of vomiting. All of these patients
also received cisplatin therapy. The data are being analyzed for this study
and the report is being prepared.

Clinical Study 5
In a phase II evaluation of oral PXD in combination with cisplatin or paclitaxel
in women with a history of platinum/taxane-refractory or -resistant epithelial
ovarian, fallopian tube, or primary peritoneal cancers, patients with
recurrent (n=60) late-stage epithelial cancer are being treated with weekly

Table 1: Phase I and II Clinical Studies

<table>
<thead>
<tr>
<th>Dose Stratum (mg)</th>
<th>n</th>
<th>PSA Decline*</th>
<th>Patients with PD by 6 Months**</th>
<th>Time to Progression (Weeks)***</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>35</td>
</tr>
<tr>
<td>80</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>56</td>
</tr>
<tr>
<td>200</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>70</td>
</tr>
<tr>
<td>400</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td>86</td>
</tr>
</tbody>
</table>

* Prostate-specific antigen (PSA) decline defined as a decrease in PSA level to at least 50% of baseline for at least one month.
** Disease progression (DP) defined as an increase in PSA levels of 25% compared with baseline and/or deterioration in disease status as determined clinically or radiologically.
*** Time patient remained on phenoxodiol therapy; therapy stopped when patients showed evidence of disease progression based on either PSA levels or evidence of new lesions.
**** Three patients remained on therapy at last follow-up.

Table 2: Details of Phenoxodiol Therapy in Seven Patients with Hematological Cancers

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Dosages (mg/kg/12 Hours)</th>
<th>Duration of Therapy (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>16, 18, 26</td>
<td>51</td>
</tr>
<tr>
<td>02</td>
<td>16, 26, 36</td>
<td>43</td>
</tr>
<tr>
<td>03</td>
<td>16, 26</td>
<td>29</td>
</tr>
<tr>
<td>04</td>
<td>13, 23, 26, 36</td>
<td>47</td>
</tr>
<tr>
<td>05</td>
<td>13, 18, 23, 26, 36</td>
<td>30</td>
</tr>
<tr>
<td>06</td>
<td>26, 36, 47, 58</td>
<td>15</td>
</tr>
<tr>
<td>07</td>
<td>18, 26, 47</td>
<td>42</td>
</tr>
</tbody>
</table>

NADHoxidase (tNOX), which is thought to be involved in the transfer of
electrons from intracellular NADH to an extracellular acceptor via plasma
membrane ubiquinone.11

Clinical Studies
There have been eight clinical studies in which patients have been treated
with oral PXD.

Clinical Study 1
In the phase Ila safety and efficacy study of PXD in males with hormone-
refractory prostate cancer (HRPC) trial, 30 patients enrolled in a treatment
cycle of 28 days where PXD was given every eight hours for 21 days at
dosages of 20, 80, 200, or 400mg and, prior to a protocol amendment, two
patients were enrolled at 360mg per dose. Patients received six treatment
cycles (six months) or were treated until there was disease progression. At
six months, those patients considered by the principal investigator to be deriving
a clinical benefit were continued on PXD therapy.

Twenty-five evaluable patients with HRPC have been studied. Six patients
were treated in 20 and 80mg dose strata, five at 200mg dose levels, and
eight at the 400mg dose level. There were no drug-associated toxicities or
intolerance in any dose strata for the six months of treatment. The
eight-hourly dosing regimen resulted in steady-state plasma levels of drug
with no accumulation over time. The mean steady-state PXD levels in the 20,
80, 200, and 400mg dose strata were 1.57, 8.14, 16.31, and 27.19µg/ml,
respectively. The clinical outcomes of the study are summarized in Table 1.

Clinical Study 2
In a phase Ila evaluation of oral PXD in patients with hematological cancers,
seven patients were evaluated with oral PXD every 12 hours over 42 days with
an intended dose escalation every 14 days. The lowest dose stratum was
13mg/kg and the highest dose stratum was 58mg/kg. The dosages used and
duration of treatment are shown in Table 2. There were no drug-associated
toxicities or intolerance in any dose strata with PXD. No evidence of tumor
response was observed, and the study was terminated due to the inability of
the blood to deconjugate glucuronide or sulfate moieties of PXD. Combined
with the high level of susceptibility of PXD to conjugation, this made
hematological cancers an inappropriate clinical target for PXD.

Clinical Study 3
In a phase Ila safety and efficacy study of the neoadjuvant use of oral PXD
in women with a primary diagnosis of squamous cell carcinoma or
adenocarcinoma of the cervix, vagina, or vulva, patients were treated with
PXD 50 (n=6), 100 (n=10), or 400mg (n=10) eight-hourly for 28 consecutive
days on a neoadjuvant basis prior to surgical resection; 26 patients completed treatment. Tumor response was assessed over the
28-day treatment period by both a change in tumor burden using the
Response Evaluation Criteria in Solid Tumors (RECIST) and by
histochemical evidence of a biological effect (e.g. apoptosis). No
incidences of PR have been recorded (against RECIST criteria), although
many patients have shown a reduction in the sum longitudinal diameter
of between 20 and 27%. Of the six patients treated with PXD 50mg, the
incidence of stabilized disease (SD) and disease progression (DP) was two
and four, respectively. Of the eight patients treated with PXD 200mg, the
incidence of SD and DP was eight and zero, respectively. The data for the
400mg stratum have yet to be collected. This trend suggests an
antitumor effect of PXD in this setting, a fact supported by histochemical
evidence showing an increase in apoptotic index and decrease in mitotic
index in the 200mg stratum. There was one serious adverse event (SAE)
deemed definitely related to PXD: prolonged bleeding time in a patient on
the 400mg arm. The data are currently being cleaned and will be available
for analysis shortly.

Clinical Study 4
In a current phase Ib safety and efficacy study of PXD in combination
with cisplatin or carboplatin in patients with advanced or metastatic
cancer not suitable for surgery or radiotherapy, 25 patients were treated
with a oral PXD in combination with cisplatin or carboplatin. The primary
objective of this study was to determine the recommended phase II dose
of PXD in combination with cisplatin or carboplatin. Patients were given
oral PXD 50 (n=6), 100 (n=6), 400 (n=6), or 800mg (n=7) every eight
hours daily for 10 consecutive days followed by 11 days of rest. In
addition, patients received either cisplatin 50mg/m² on days two and
nine of each 21-day cycle or carboplatin area under the curve (AUC)=5
on day three every 21 days. The dose-limiting toxicity (DLT) was diarrhea
at the 800mg dose level and the maximum tolerated dose (MTD) was
determined to be 400mg orally every eight hours. In this trial there were
four serious adverse events: two cases of diarrhea, one case of
ventricular arrhythmia, and one case of vomiting. All of these patients
also received cisplatin therapy. The data are being analyzed for this study
and the report is being prepared.

Clinical Study 5
In a phase II evaluation of oral PXD in combination with cisplatin or paclitaxel
in women with a history of platinum/taxane-refractory or -resistant epithelial
ovarian, fallopian tube, or primary peritoneal cancers, patients with
recurrent (n=60) late-stage epithelial cancer are being treated with weekly
intravenous (IV) PXD 3mg/kg or oral PXD 400mg every eight hours in combination with IV weekly carboplatin (AUC=2), IV weekly cisplatin (40mg/m²), and paclitaxel (80mg/m²) IV weekly (six arms).

Initial results were encouraging, with an objective response rate of 30 and 14% for the PXD plus cisplatin and PXD plus paclitaxel groups, respectively, and an overall disease control rate of 75% for PXD plus cisplatin and 76% for PXD plus paclitaxel. There were eight serious adverse events reported in this trial: skin rash (n=1), diarrhea (n=1), pancytopenia (n=1), peripheral sensory neuropathy (n=1), thrombocytopenia (n=1), hypersensitivity reaction (n=1), neutropenic sepsis (n=1), and febrile neutropenia (n=1). The data are currently being analyzed.

Clinical Study 6

A multicenter, randomized, double-blind phase III efficacy study is currently under way comparing PXD (oral dosage form) in combination with carboplatin versus carboplatin with placebo in patients with platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian, or primary peritoneal cancer following at least second-line platinum therapy. This global phase III trial of 340 patients will expand on phase II clinical evidence that PXD has the ability to reverse chemoresistance to platinum drugs in late-stage ovarian, fallopian, and primary peritoneal cancers.

Patients are those who have received at least two lines of platinum therapy (cisplatin or carboplatin) and found that their tumor is platinum-resistant (disease progression within six months of completion of a platinum course of therapy) or platinum-refractory (disease progression while on platinum therapy). This cohort of patients are unlikely to respond to further treatment with two-, three-, or four-week platinum regimens, but may be responsive to a more dose-dense therapy regimen of weekly platinum. The treatment arms are PXD two 200mg capsules every eight hours plus weekly carboplatin AUC=2 for four weeks or weekly carboplatin AUC=2 plus two oral placebo capsules 200mg every eight hours for four weeks. One cycle is four weeks.

Patients will stay on medication until progression or reasons deem otherwise. The primary end-point is progression-free survival (PFS)—projected median PFS times for the two groups being eight and five months, respectively—and the secondary end-point is overall survival (OS). RECIST based on helical computed tomography (CT) scans will be used to determine disease progression, tumor response rate, and duration of response. This protocol has gained approval by the FDA under Special Protocol Assessment (SPA).

Clinical Study 7

A randomized, placebo-controlled phase Ib/Ia safety, tolerability, and efficacy study of oral PXD in combination with docetaxel versus docetaxel alone in patient with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer is under way at Yale Cancer Center. A total of 60 patients will be enrolled and randomly allocated to either of the following two treatment arms: arm one—oral PXD 400mg every eight hours in combination with docetaxel IV 36mg/m² weekly; arm two—placebo every eight hours in combination with docetaxel IV 36mg weekly. Patients will be treated for three cycles; one cycle consists of three weeks on and one week off.

The primary objective is to determine the safety and tolerability of combinational therapy of oral PXD and docetaxel in patients with recurrent ovarian cancer. The secondary objectives are to determine the effect of PXD on the toxicity of docetaxel using a weekly treatment regimen, to determine whether combinational therapy of PXD plus docetaxel is more efficacious than docetaxel therapy alone, to determine whether combinational therapy of PXD plus docetaxel affects blood levels of either drug, and to determine phenotypic differences in the tumor cells of ‘responders’ and ‘non-responders.’

Clinical Study 8

A phase II trial of PXD is being conducted at Yale Cancer Center and West Haven Veterans Administration of Connecticut in patients with castrate and non-castrate prostate cancer. A total of 60 eligible patients will be enrolled: 25 chemotherapy-naïve patients with metastatic prostate disease are (hormone-refractory prostate cancer; Group A) and 35 patients with rising PSA after radical prostatectomy or radiotherapy who are non-castrate androgen-dependent (Group B). All patients will be treated with oral PXD 400mg every eight hours alone for 28 consecutive days (one cycle). Treatment outcome will be evaluated after each cycles (12 weeks) of PXD treatment (immediately prior to cycle four). The primary objective for this study is to determine the proportion of those treated with PXD who have a 50% post-therapy prostate-specific antigen (PSA) decline at 12 weeks.

Conclusion

The development of chemoresistance is a major limitation in the treatment of cancers. PXD is a novel biomodulator that has been shown to affect specific survival and death pathways. More importantly, it has been shown to reverse chemoresistance in vitro. In humans, it is well tolerated and has shown evidence of activity. The major challenge in the future is the development of an appropriate dosage form for PXD for its successful use in cancer treatment.